EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Alkaline phosphatase refines FIB-4–based prediction of liver outcomes and mortality in MASLD

Or Shimoni, Emma Hajaj, Shiri Kushnir, Amir Shlomai

Digestive and Liver Disease · 2026-10

DOI: 10.1016/j.dld.2026.10.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive and Liver Disease, 2026-10. Verfasst von Or Shimoni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine D, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: FIB-4 is recommended for first-line MASLD risk stratification but excludes cholestatic liver enzymes. AIMS: To assess whether alkaline phosphatase (ALK) improves prediction of major adverse liver outcomes (MALO) and mortality beyond FIB-4. METHODS: In this retrospective cohort study (2004-2025), adults aged ≥35 years with MASLD or type 2 diabetes with BMI >27 kg/m² were classified by baseline ALK ≥120 U/L and age-adjusted FIB-4 strata. Cause-specific Cox models assessed 10-year MALO and mortality. RESULTS: Among 388,933 participants (mean age 59 years; 53% female), 35,073 (9%) had elevated ALK. Ten-year MALO incidence was higher with elevated ALK across low (1.5%vs 1.1%), intermediate (2.8%vs 1.6%), and high FIB-4 strata (11.9%vs 4.5%). Compared with low FIB-4 and normal ALK, adjusted hazard ratios for MALO were 1.41 (95% CI 1.25-1.59), 2.58 (2.17-3.07), and 9.57 (8.06-11.3) for low, intermediate, and high FIB-4 with elevated ALK, respectively. FIB-4 and ALK were independently associated with MALO, with significant interaction (P < 0.001) and improved event reclassification. Findings were consistent after incorporating GGT. CONCLUSIONS: Elevated ALK identifies MASLD patients at higher liver-related risk and modifies FIB-4-associated risk. Incorporating cholestatic enzyme status into FIB-4-based assessment may improve non-invasive triage and referral decisions.

Schlagwörter

Stichwörter der Autor:innen

Alkaline phosphataseCholestasisFIB-4MASLD

Autor:innen und Institutionen

  • Department of Medicine D, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel.
  • Research Authority, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
  • Department of Medicine D, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel; Laboratory of Liver Research, The Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel; Faculty of Medical and…

Zitieren

APA

Shimoni, O., Hajaj, E., Kushnir, S., & Shlomai, A. (2026). Alkaline phosphatase refines FIB-4–based prediction of liver outcomes and mortality in MASLD. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.10.026

Vancouver

Shimoni O, Hajaj E, Kushnir S, Shlomai A. Alkaline phosphatase refines FIB-4–based prediction of liver outcomes and mortality in MASLD. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.10.026

BibTeX
@article{Shimoni2026,
  author = {Shimoni, Or and Hajaj, Emma and Kushnir, Shiri and Shlomai, Amir},
  title = {Alkaline phosphatase refines FIB-4–based prediction of liver outcomes and mortality in MASLD},
  journal = {Digestive and Liver Disease},
  year = {2026},
  doi = {10.1016/j.dld.2026.10.026}
}
Kostenlos starten →